http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108403692-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 |
| filingDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108403692-B |
| titleOfInvention | Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor |
| abstract | The present invention relates to the new opplication of hydrochloric acid Atipamezole, specially application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor.Hydrochloric acid Atipamezole does not have significant difference to the rejection ability of each isodynamic enzyme, is especially significantly stronger than 1-ABT to the inhibiting effect of CYP2C9, and species variation is small.The present invention is using veterinary drug hydrochloric acid Atipamezole as a new generation's P450 enzyme nonspecific inhibitor, it can be not only used for outside animal body, In vivo study, it can also be used for human vitronectin system research, it and since the inhibiting effect of hydrochloric acid Atipamezole is drug prototype is not metabolite, preincubate need not be carried out when carrying out in vitro study as instrument medicine, it need not be administered in advance when In vivo study, there is the clear superiority for substituting existing classical tool medicine 1-ABT. |
| priorityDate | 2018-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 331.